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Hamilton, Ontario, Canada; and §Ontario Cancer Institute/University Health Network, Toronto, Ontario, CanadaABSTRACT Photodynamic therapy (PDT) is generally based on the generation of highly reactive singlet oxygen (1O2) through
interactions of photosensitizer, light, and oxygen (3O2). These three components are highly interdependent and dynamic, result-
ing in variable temporal and spatial 1O2 dose deposition. Robust dosimetry that accounts for this complexity could improve treat-
ment outcomes. Although the 1270 nm luminescence emission from 1O2 provides a direct and predictive PDT dose metric, it
may not be clinically practical. We used 1O2 luminescence (or singlet oxygen luminescence (SOL)) as a gold-standard metric
to evaluate potentially more clinically feasible dosimetry based on photosensitizer bleaching. We performed in vitro dose-
response studies with simultaneous SOL and photosensitizer fluorescence measurements under various conditions, including
variable 3O2, using the photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC). The results show that SOL was always
predictive of cytotoxicity and immune to PDT’s complex dynamics, whereas photobleaching-based dosimetry failed under
hypoxic conditions. However, we identified a previously unreported 613 nm emission from mTHPC that indicates critically
low 3O2 levels and can be used to salvage photobleaching-based dosimetry. These studies improve our understanding of
PDT processes, demonstrate that SOL is a valuable gold-standard dose metric, and show that when used judiciously, photo-
bleaching can serve as a surrogate for 1O2 dose.INTRODUCTIONAlthough photodynamic therapy (PDT) has emerged as
a viable treatment for several oncological and nononcolog-
ical indications, many clinical results have been suboptimal
(1,2). Currently, most PDT treatments are based on empir-
ical administered photosensitizer and light doses, without
adjustment for the often large inter- and intratreatment vari-
ations in photosensitizer pharmacokinetics/distribution,
tissue optics, and/or tissue oxygenation. Further, dynamic
interactions can occur among the photosensitizer, light,
oxygen, and tissue properties. For example, both photosen-
sitizer and 3O2 molecules can be consumed by photochem-
ical reactions during PDT. These consumption rates are not
constant, which means the delivered dose can vary markedly
within and between treatment sites. It has been proposed
that robust, personalized dosimetry may be able to reduce
inter- and intratreatment variability, and thus ultimately
improve treatment outcomes (3–5).
PDT is based on the photosensitized generation of highly
reactive and cytotoxic singlet oxygen (1O2) from ground-
state molecular oxygen (3O2) in tissue (6). It is well
accepted that 1O2 is the primary cytotoxin in PDT for
most photosensitizers of interest (7) and that the amount
of 1O2 that reacts is the basis of PDT dose (8). There are
three main approaches to PDT dosimetry (9): explicit,
implicit, and direct. Explicit dosimetry measures the PDT
inputs (i.e., light, photosensitizer, and [3O2]) and incorpo-Submitted June 9, 2011, and accepted for publication December 1, 2011.
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Even under static conditions, it is technically challenging
to measure all three parameters, and, given that they are
also dynamically interdependent, it is difficult and often
impractical to achieve accurate and complete dose quantifi-
cation. So-called implicit dosimetry monitors the dynamic
PDT process indirectly by measuring the decrease in photo-
sensitizer fluorescence (and/or absorption or phosphores-
cence) during light treatment, which depends on and
hence integrates all three PDT factors. Investigators have
developed biophysical models to interpret and correlate
changes in photosensitizer fluorescence to the amount of
1O2 generated, i.e., to the effective PDT dose delivered
(10,11), but so far they have not demonstrated that these
changes are robust under all clinically relevant conditions.
Finally, direct dosimetry measures the primary effector of
PDT damage, namely, the 1O2 itself, through its 1270 nm
emission (12), denoted here as the singlet oxygen lumines-
cence (SOL).
In principle, direct dosimetry effectively collapses the
complex interdependent PDT processes onto a single metric
that should accurately reflect the PDT dose, and it has been
shown that cumulative SOL photon counts (cSOL) correlate
with and can be predictive of the treatment outcomes, both
in vitro (8) and in vivo (13). Of particular relevance here is
the demonstration that a universal in vitro 1O2 dose-response
curve (i.e., the surviving fraction of cells versus cSOL) can
be generated that is independent of the light dose, photosen-
sitizer concentration, oxygenation, subcellular localization
(which depends on the incubation time) for a given celldoi: 10.1016/j.bpj.2011.12.043
662 Jarvi et al.type, and SOL collection geometry. A clear advantage is the
substantially reduced need for photochemical reaction
models and approximations compared with implicit dosim-
etry. However, the SOL signal is ultra weak because, as
a result of its high biomolecular reactivity, 1O2 a markedly
reduced lifetime and low radiative probability (~108) in
biological environments. This is exacerbated by the low
quantum efficiency and appreciable dark-count background
of available photomultiplier tube (PMT) detectors in the
near-infrared (NIR) spectral region around 1270 nm. As
a result, SOL detection is confounded by other, much
stronger sources of luminescence (14), including endoge-
nous cell/tissue and photosensitizer fluorescence and
phosphorescence. The low signal sets practical limits to
the use of SOL, including the inability to use fiber-optic
probes to collect the 1O2 photons and the need to integrate
the signal over a substantial volume of irradiated tissue
(15). In addition, NIR-PMTs are much more expensive
than those required for steady-state fluorescence measure-
ments in the visible spectrum. As a result, direct 1O2
monitoring may not feasible in many clinical situations,
and more cost-effective and technically simpler techniques
that accurately monitor the delivered PDT dose would be
valuable.
Exploiting the photosensitizer photobleaching as a surro-
gate for 1O2 dose is a potential approach (11). Photosensi-
tizer fluorescence is often used to monitor changes in the
photosensitizer during PDT because it is relatively easy to
measure and more sensitive than ground-state absorption
spectroscopy (16). The framework for this dose metric is
that 1O2 is the primary cause of the photobleaching (and
of the cytotoxic PDT effect). Although data indicate that
the photobleaching for many photosensitizers is predomi-
nantly 1O2-mediated, singlet- or triplet-state-mediated
bleaching is also possible (10,17). The studies presented
here focus on the photosensitizer meso-tetra(hydroxy-
phenyl)chlorin (mTHPC). In experiments conducted to
date, mTHPC photobleaching was explained by 1O2-medi-
ated reactions alone (11,18). Thus, Dysart et al. (11) demon-
strated that photobleaching-based dosimetry could generate
a universal dose response curve for mTHPC-PDT in cells in-
vitro under a range of experimental conditions, in similarity
to the successful performance of cSOL counts (8).
Our goal in this work was to perform a direct comparison
of the two PDT dosimetry techniques (SOL and photo-
bleaching) and develop a method whereby SOL measure-
ments can also help identify those conditions under which
photobleaching is reliable and predictive, and can be used
when SOL monitoring is not feasible. Conversely, photo-
bleaching analysis may help to clarify SOL kinetics and
identify the limitations of SOL monitoring in translating it
to the clinic. In addition, we sought to provide a more
complete understanding of PDT photophysics and photo-
chemistry, and their impact on the effective PDT dose
and treatment response. To address these objectives, weBiophysical Journal 102(3) 661–671measured SOL and photosensitizer fluorescence photo-
bleaching simultaneously during mTHPC-PDT in vitro
under a range of conditions (i.e., photosensitizer concentra-
tion, fluence rate, fluence, and oxygenation). We chose
mTHPC as the model photosensitizer for these studies
because it has been well characterized in previous photo-
bleaching studies and is also in clinical use or trials for
various solid tumors.THEORY
Time-resolved SOL detection
The theory underlying time-resolved SOL kinetics and
detection was previously described in detail (12,19) and is
summarized in the Supporting Material. It relies on time-
resolved photon counting to sample the 1270 nm SOL
peak and wavelengths on either side of the peak to remove
other background sources of NIR luminescence.Photosensitizer photobleaching
As shown by Dysart et al. (11), the change in the ground-
state (S0) photosensitizer concentration due to
1O2-mediated
photobleaching can be expressed by the following differen-
tial equation:
d½So
dt
¼ kOSð½So þ dÞ½1O2: (1)
Thus, reactions between 1O2 and ground-state photosensi-
tizer molecules governed by the bimolecular reaction rate
constant kOS lead to irreversible degradation of the photo-
sensitizer, as well as oxygen consumption (19). The
d term accounts for reaction of a 1O2 molecule with the
same photosensitizer molecule involved in its generation.
At the low concentrations typically found in cells and
tissues (less than approximately micromolar), these are the
dominant reactions, because singlet oxygen has a high prob-
ability to react with other targets before it can diffuse to
another sensitizer molecule. d is given approximately by
d ¼ 1
d3NA
; (2)
where NA is Avogadro’s number and d is the mean
1O2 diffu-sion distance, defined as
d ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
6DtD
p
; (3)
where D is the diffusion coefficient of 1O2 and tD is the
1O2
lifetime.
The instantaneous 1O2 concentration can be determined
by rearranging Eq. 1 to
½1O2 ¼  1
kOSð½So þ dÞ
d½So
dt
: (4)
Photodynamic Therapy Dosimetry 663Because 1O2 is the primary cytotoxin in PDT, the PDT dose
is the cumulative 1O2 generated, which is assumed to be
equal to the amount of 1O2 reacted, other deactivation path-
ways being at least an order of magnitude less probable.
Hence, the PDT dose over a time T is
Dose ¼
Z T
0
½1O2ðtÞ
tD
dt (5)
1
 ½So þ d ¼
tD x kOS
ln oð½SoðTÞ þ dÞ : (6)
The PDT dose can then be calculated from photosensitizer
photobleaching (decrease in [S0]), if 1/(tD x kOS) and
d can be determined experimentally, as described below.MATERIALS AND METHODS
SOL and photosensitizer fluorescence
measurement system
We measured the SOL and photosensitizer fluorescence using the system
shown in Fig. S1. The LabView-controlled system is similar to that
described by Jarvi et al. (19) and the light collection geometry is the
same. The sample was placed on a heated stirrer plate and irradiated with
a pulsed (~10 ns), frequency-doubled Nd:YLF laser (Crystalaser, Reno,
NV). The irradiation spot size diameter was 8 mm, the laser pulse repetition
rate was 10 kHz, and the excitation/treatment fluence rate was controlled
with neutral density filters.
The fluorescence collection comprised a 590 nm long-pass filter (New-
port, Irvine, MA) in front of an SMA-fiber collimator (Thorlabs, Newton,
NJ) connected to a 400 mm core diameter optical fiber (Thorlabs) that deliv-
ered light to a USB-controlled CCD spectrophotometer (USB-2000; Ocean-
Optics, Dunedin, FL). The luminescence spectrum from 400 to 900 nm was
sampled every 5 s with the use of OOIBase 32 software (OceanOptics). The
524 nm excitation light was not completely filtered out and served as a refer-
ence signal, as described below. The integration time was set at either 250
or 500 ms, respectively, for the high- and low-light fluence rates noted
below.PDT treatments and luminescence measurements
Photosensitizer and AML-5 leukemia cells were prepared as described in
the Supporting Material. After a 6 h incubation period, cells were centri-
fuged at 3000 rpm for 10 min at 4C, resuspended in fresh medium, and
then centrifuged once more to minimize extracellular photosensitizer.
The suspension was adjusted to a concentration of 40  106 cells/ml, and
2.5 ml was transferred to a 3.5 ml, 10 mm pathlength quartz cuvette
(NSG Precision Cells, Farmingdale, NY) placed on the heated-stirrer plate
(32–35C) in front of the luminescence measurement system. The cuvette
was open at the top, so that cells were exposed to ambient air unless other-
wise stated. The period from the end of the final centrifuging to the begin-
ning of the measurements was 12 5 3 min.
Accounting for the beam diameter (8 mm), light scattering by the cell
suspension, and assuming that the 2.5 ml sample was well mixed, the
average fluence rate to which the cells were exposed was either 55 or
110 mW cm2. The NIR luminescence signal was sampled for 20 or
40 s, respectively, at each NIR bandpass filter using the following filter
sequence per acquisition cycle: 1270, 1270, 1300, and 1240 nm (i.e., the
1270 nm SOL was sampled 50% of the time). This sequence was repeatedfour times. The corresponding total treatment duration was either 336 or
660 s, to give the same total fluence in all cases. Five cell samples were
used for each combination of photosensitizer and fluence rate, along with
four light-only control samples.
At defined time points during irradiation, we removed 15 ml aliquots
from the cuvette without interrupting the measurements and added them
to 1 ml of fresh medium. Early in the treatment, samples were taken
more frequently to resolve the shape of the dose-response curves. The
samples were then used for the colony-forming assay as described in the
Supporting Material.
In summary, the incubation concentration, cell density, sample volume,
light fluence rate, fluence, and detection geometry were well controlled.
As in previous in vitro studies (8), the exact cell confluence and cell cycle
of the cell suspensions were not controlled or measured. Thus, they varied,
which influenced the metabolic status, photosensitizer uptake, and the intra-
cellular photosensitizer concentration/localization. In addition, differences
in cell metabolic status, cell handing time, and commencement of the PDT
treatments contributed to variable [3O2] between samples at the beginning
of treatment. This scenario likely mirrors some of the clinical variability
seen in PDT treatments, and is useful to fully evaluate the efficacy of the
SOL and photosensitizer photobleaching PDT dose metrics in eliminating
the dependence on biological and treatment variables.Explicit ground-state triplet oxygen
measurements
We measured the sample pO2 (mm Hg) as previously described (19) using
a calibrated Clark-style polarographic electrode (Eppendorf, Hamburg,
Germany) placed at the center of the cuvette. The partial pressure was con-
verted from mmHg to molar concentration (mM) using the following
approximation: 760 mm Hg ¼ 220 mM at 35C.Further details
Additional details regarding the preparation of the photosensitizer, cell
culture and preparation, colony-forming assays, quantification of the intra-
cellular photosensitizer concentration, singular value decomposition (SVD)
analysis of the fluorescence spectra, determination of the intracellular
photosensitizer and SOL fraction, and the reoxygenation and hypoxia
experiments can be found in the Supporting Material.RESULTS
Fluorescence measurements
The photosensitizer fluorescence signal is plotted as a func-
tion of treatment fluence for selected experiments in Fig. 1.
This is expressed as the ratio of the 652 nm emission to the
523 nm excitation derived from an SVD fit to the acquired
spectra (see Supporting Material for more details) and is
therefore independent of the excitation fluence rate. The
(initial) fluorescence signal scaled with the incubation
concentration. The initial rate of photobleaching (as a func-
tion of fluence up to ~8 J cm2) was not fluence-rate-depen-
dent but exhibited a greater than proportional dependence
on the mTHPC concentration, because some of the photo-
bleaching derives from 1O2 generated by one photosensi-
tizer molecule diffusing and reacting with a nearby
photosensitizer molecule. These observations are consistent
with previous mTHPC photobleaching results reported by
Dysart et al. (11,20).Biophysical Journal 102(3) 661–671
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FIGURE 2 (a) Unprocessed fluorescence spectra at discrete fluence
values, showing a decrease in the 652 mTHPC emission with increasing flu-
ence. The inset is a magnification of the 550–650 nm region, showing the
increasing 613 nm signal with fluence. (Note that this signal overlaps
with the cell autofluorescence spectrum.) (b) The measured 652 nm fluores-
cence signal and the 613 signal derived from the spectral fitting of the data
in panel a as a function of fluence. Both signals are normalized to the exci-
tation light intensity. The onset of the 613 signal coincides with the sudden
change in the rate of loss of the 652 nm fluorescence signal. (c) Correspond-
ing pO2 data, showing a rapid decrease during PDT treatment to near zero.
Also plotted are the cumulative SOL counts, showing an initial increase and
then a plateau once the oxygen has been depleted. The gray dashed lines in
b and c indicate when the pO2 reaches < 5 mM.
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FIGURE 1 Sample fluorescence (corrected for incident power) measured
during mTHPC-mediated PDT for select experiments, representing
different incubation concentration and fluence rates. An additional data
set is presented (black >) for cells treated under hypoxic conditions and
another (blue,) for cells incubated with 0. 15 mg/ml mTHPC and irradi-
ated at 110 mW cm2, representing a sample that exhibited a constant pho-
tobleaching behavior.
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hypoxic conditions than in aerated samples, as one can
see in Fig. 1 by comparing the aerated and N2-purged
hypoxic samples treated at 0.25 mg/ml and 110 mW cm2.
For all samples at 0.25 mg/ml, the mean (51 SE) fluores-
cence signal under hypoxic conditions was about half that
of the aerated samples (0.24 5 0.14 compared with
0.525 0.27; p ¼ 0.014). This dependence of fluorescence
intensity on [3O2] was reported previously (21,22) and is
likely due to altered mTHPC photophysics as the triplet-
state lifetime (tT) increases. We discuss this further below.
Another significant observation is the sudden change in
the rate of loss of fluorescence for several of the treated
samples. (Note: We do not denote this as a change in the
photobleaching rate per se, for reasons detailed below.)
For example, for 0.25 mg/ml mTHPC and 55 mW cm2,
the fluorescence decreased linearly with fluence up to
~9 J cm2, at which point there was a sudden decrease
with a pronounced exponential decay that returned to the
initial rate by 20 J cm2. This apparent multiphase behavior
occurred in a majority of the samples, but in some cases,
especially at lower drug concentration, the fluorescence
decreased as a single exponential. The sudden transition in
the measured bleaching rate was reported for mTHPC-medi-
ated PDT of normal skin in vivo by Finlay et al. (23) but has
not been previously observed in vitro.
This discontinuity in slope coincided with the pO2
decreasing below 10 mM. For example, a comparison of
Fig. 2 b (A, left axis) with Fig. 2 c (x, left axis) shows
that the pO2 decreases rapidly from the start of irradiation
due to photochemical and metabolic consumption, and
approaches zero at the fluence (~10 Jcm2) corresponding
to the change in the apparent bleaching rate. We also deter-Biophysical Journal 102(3) 661–671mined the 3O2 depletion indirectly by examining the SOL
signal, which intrinsically depends on oxygen concentra-
tion. The sudden change in the fluorescence decay rate
corresponds in time with a sudden drop in the detected
Photodynamic Therapy Dosimetry 665SOL count rate (data not plotted) and with the start of
a plateau in the cSOL counts, plotted on the right vertical
axis in Fig. 2 c. To summarize, when [3O2] approaches
zero, no further SOL counts are detected, the cumulative
(cSOL) counts reach a plateau, and there is a sudden
increase in the apparent rate of sensitizer photobleaching.613 nm emission
In Fig. 2 a, the fluorescence spectra from one cell suspen-
sion are plotted for discrete fluence values. The 652 nm
peak decreased with increasing fluence, consistent with
photobleaching. Under closer examination (Fig. 2 a, inset),
a small peak at 613 nm was detected that increased with
treatment fluence. (Note: This figure is labeled ‘‘lumines-
cence’’ because it is unclear whether the 613 nm emission
is fluorescence or phosphorescence.) At the first acquisition
(0 J cm2), the 613 nm emission is indistinguishable
from the broad 600–630 nm autofluorescence signal
(see Fig. S2). The 613 nm emission was separated from
the background via SVD analysis and is plotted in Fig. 2 b
versus fluence, together with the 652 nm mTHPC fluores-
cence. The 613 nm emission was first detected at the point
where the 652 nm fluorescence peak began to decrease
rapidly (~10 J cm2) and thereafter increased with treatment
fluence. To our knowledge, this emission has not been
previously reported. It was not detected above background
when the pO2 was >10 mM, and increased markedly below
this level. Based on eight samples in which this signal
was detected, the mean (51 SE) pO2 at the onset (defined
as the peak in the second derivative of signal intensity as
function of fluence) was 4.75 5 1.4 mM, which is much
less than the concentration at the beginning of treatment
(~100 mM).Reoxygenation
To further characterize the [3O2] dependence of the 652 nm
and 613 nm signals, we performed reoxygenation experi-
ments (see Fig. S4 for data plots). When carbogen (95%
oxygen, 5% CO2) was gently bubbled into the sample, the
613 nm emission decreased rapidly and the 652 nm fluores-
cence increased in a near step-like manner. The latter is not
an artifact due to increased scattering from gas bubbles,
because there was minimal change in the transmission of
the 523 nm excitation light (data not shown). After the carb-
ogen bubbling stopped, the 613 nm emission increased
slightly and then fell again during the second cycle of
bubbling, whereas the mTHPC fluorescence increased.
Correspondingly, upon addition of carbogen, the SOL count
rate increased to levels comparable to the initial rate,
decreased after the carbogen flow was shut off, and
increased again upon regassing, resulting in step-like
changes in the cSOL counts. Similar results were obtained
when the sample was initially purged with N2, except thatthe relative increase in the 652 nm emission after reoxyge-
nation was even greater. For example, the ratio of signals
between immediately post-carbogen and immediately pre-
carbogen during the first gassing cycle was 1.24 5 0.12
(n ¼ 5) for the aerated and 1.48 5 0.08 (n ¼ 3) for the
N2-purged samples. These data indicate that the changes
in the 652 nm fluorescence that occurred at low pO2 are
not the result of permanent photobleaching, and the
613 nm emission does not originate from a stable photo-
product, because the changes in both signals can be
reversed.Photobleaching-derived estimate of 1O2 dose
Using the fluorescence data, including the representative
data in Fig. 1, and estimated d-value (see Supporting Mate-
rial), we calculated the 1O2 dose from Eq. 6. Because tD and
kOS are not known, the data are presented as unitless dose
values, (tD  kOS)  1O2 dose (11). This photobleaching-
derived 1O2 dose is plotted versus fluence in Fig. 3 a for
all of the samples. These results are significantly skewed
by the changes in fluorescence at low [3O2]. Thus, in
samples that exhibited a significant reduction in fluores-
cence coinciding with 3O2 depletion, there was a resulting
large increase in the calculated 1O2 dose. This contributed
to the large variance in the calculated 1O2 dose when plotted
against fluence even for samples treated with the same
mTHPC incubation concentration and fluence rate. More-
over, the 1O2 doses calculated for the samples that exhibited
these effects were ~10-fold higher than those reported by
Dysart et al. (11).
The onset of the 613 nm emission was then used to
stratify the data. Specifically, the photobleaching data
were truncated 1 J cm2 before the appearance of the
613 nm emission. As shown in Fig. 3 b, the 1O2 dose derived
from the photobleaching analysis was then plotted versus
fluence, and a greater 1O2 dose was found for the higher
incubation concentrations. By selecting only the data above
the critical 3O2 level, we obtained a range of calculated
1O2
doses comparable to those reported by Dysart et al. (11).
However, there was significant variability in the 1O2
dose under similar fluence rate and incubation concentra-
tions. This same variability was observed in the cSOL
counts and surviving fraction versus fluence (see below),
as well as in a previous study (8), and is attributed to varia-
tions in photosensitizer uptake and/or [3O2] from sample to
sample.SOL measurements
The SOL counts were corrected for the influence of time
gating and changes in the decay lifetime as previously
described (19). The SOL count rate decreased with
increasing fluence due to a combination of 3O2 consumption
(both photochemical and metabolic) and mTHPCBiophysical Journal 102(3) 661–671
FIGURE 4 Singlet oxygen dose derived from the photobleaching
analysis (Eq. 6) versus the corrected cSOL counts. Only fluorescence
data before the onset of the 613 emission are included. Each data point
represents the mean value (n ¼ 5) at a given treatment fluence for the
experimental conditions listed. A linear fit shows a strong correlation
(R2 ¼ 0.93) between the two methods of estimating the singlet oxygen
dose. The dashed line and solid square symbols show the 0.15 mg/ml,
100 mW cm2 data if all of the fluorescence measurements are used,
including those acquired after the onset of the 613 nm emission.
a
b
c
FIGURE 3 (a) Singlet oxygen dose calculated from fits to Eq. 6 using all
the fluorescence measurements and the d estimate versus fluence for
different incubation and fluence rate conditions. Each line represents one
sample. (b) The same data, but calculating the singlet oxygen dose using
only the measurements before the onset of detectable 613 emission, i.e.,
before marked oxygen depletion. Note the different vertical scales in panels
a and b. (c) cSOL counts versus treatment fluence. The lines are simply to
guide the eye. The cSOL counts are corrected for changes in the triplet life-
time and the integration time gate used.
666 Jarvi et al.photobleaching. A plot of SOL count rate versus fluence can
be found in Fig. S6. cSOL counts versus fluence are pre-
sented in Fig. 3 c for all samples, including the light-onlyBiophysical Journal 102(3) 661–671controls, and show the expected plateau with increasing flu-
ence, as the rate of 1O2 generation decreases with
3O2 deple-
tion and photobleaching. This is most obvious for samples
with the highest mTHPC concentration. As observed in
previous studies with the photosensitizer PpIX (8), there
was a striking variability in the cSOL counts for the same
incubation concentration and fluence rate. Further, for
a given incubation concentration and fluence rate, there
was little correlation between terminal cSOL counts and
initial mTHPC fluorescence, implying there were significant
differences in sample oxygenation at the beginning of
treatment.cSOL versus photobleaching-derived 1O2 dose
In Fig. 4 the average (n ¼ 5) 1O2 dose derived from the
photobleaching data is plotted as a function of the average
cSOL counts at each fluence value, for a given incubation
concentration and fluence rate. The error bars have been
omitted for clarity (the average relative error was 534%
and 54% for the SOL counts and photobleaching-derived
dose, respectively). A linear fit to the data showed excellent
correlation between the two dose metrics (R2 ¼ 0.93) when
only the measurements obtained before the onset of the
613 nm signal were used. By comparison, data for the
0.15 mg/ml, 100 mW cm2 samples using all of the fluores-
cence measurements, including those obtained after the
onset of the 613 nm emission and the rapid decrease in
mTHPC fluorescence, are also plotted. The slope of this
curve increases markedly at this point because of the
decrease in mTHPC fluorescence associated with oxygen
depletion.
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For the light-only controls, there was no fluence-dependent
decrease in cell clonogenicity after treatment. The surviving
fraction versus fluence shown in Fig. 5 a shows a very large
variability in survival for a given treatment fluence rate and
mTHPC incubation concentration. The cytotoxicity for
a given fluence increased with mTHPC incubation concen-
tration, and at the end of treatment was greater for the higher
fluence rate. For example, the average surviving fractions
for the 0.15 mg/ml incubated samples were 0.037 5 0.047
and 0.000875 0.00075 for 55 and 110 mW cm2, respec-
tively, although this difference was not statistically signifi-
cant. This is consistent with the SOL data, which showed
higher cSOL for the higher-fluence-rate samples.cSOL and photobleaching-derived 1O2 dose as
PDT dose metrics
The data from Figs. 3 c and 5 a were combined to generate
Fig. 5 b, which shows the surviving fraction versus cSOLa
c
FIGURE 5 (a) Surviving fraction (colony-forming assay) versus treatment fl
corrected cSOL counts from the data presented in panel a and Fig. 3 c. (c) The
dose using all the data (as in Fig. 3 a) and (d) using only the fluorescence data b
reduced c2 best fit to Eq. 8, and the dashed lines represent the 95% confidencecounts. The large variability shown for cSOL and surviving
fraction versus fluence is now greatly reduced, in similarity
to previous findings for PpIX-PDT (8). When cSOL counts
were used as the dose metric, the data collapsed (within
experimental error) onto a universal dose-response curve.
The data were fitted to a multiple-target survival model (11):
SF ¼ 1 ð1 expðD=DoÞÞn (7)
where D is the dose metric, Do is the dose required to reduce
the surviving fraction by 1/e, and n is a measure of the
shoulder width. A best fit to the data (reduced c2 ¼ 5.5,
root mean-square error (RMSE) based on log(SF) ¼ 0.45)
is also shown, together with the 95% confidence intervals.
A small shoulder is revealed (suggesting the existence of
a dose threshold and/or damage repair), followed by a mono-
exponential decrease (suggesting a single damage target).
In Fig. 5 c the surviving fraction is plotted against the
photobleaching-derived 1O2 dose, based on all the fluores-
cence measurements (data in Fig. 3 a). Not surprisingly,
the data do not collapse onto a universal curve and are notb
d
uence under a range of treatment conditions. (b) Surviving fraction versus
surviving fraction as a function of photobleaching-derived singlet oxygen
efore the onset of the 613 signal (as in Fig. 3 b). The solid black line is the
intervals. Note the different abscissa scales in c and d.
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ating particularly at higher doses. Alternatively, when only
the fluorescence measurements obtained before the onset
of the 613 nm emission are used, the dose-response curve
in Fig. 5 d closely resembles that for cSOL in Fig. 5 b,
and a better fit to Eq. 7 is achieved (reduced c2 ¼ 6.9,
RMSE ¼ 0.37). Hence, it appears that photobleaching can
be used as dose metric, provided that the sample pO2 does
not fall below 5 mM. Under more severe hypoxia, the 1O2
dose estimates from photobleaching measurements are not
valid because of the oxygen dependence of the fluorescence
signal.
Finally, the N2-purged samples (see Supporting Material)
demonstrated a decrease in fluorescence with increasing flu-
ence, minimal cSOL counts, and minimal cytotoxicity
(mean surviving fraction 0.86 5 0.36 for sensitized cells
at the end of treatment). SOL accurately predicted this
minimal cytotoxicity, whereas the photobleaching-derived
analysis falsely predicted a significant PDT dose.DISCUSSION
In this work we performed what is to our knowledge the first
direct comparison of fluorescence-based photobleaching
(implicit) dosimetry and SOL (direct) monitoring of PDT
treatments, as first proposed byWilson et al. (9). To evaluate
these two techniques, we used explicit 3O2 measurements to
examine the [3O2] dependence of both signals. The sample
[3O2] was varied through photochemical and metabolic
consumption or by controlled purging and reoxygenation
of the sample. When pO2R 10 mM, there was good corre-
lation between the two metrics and both generated dose-
response (cell survival) curves, in which the variance being
substantially reduced compared with that obtained by
simply using the light fluence as the dose metric. These
results are consistent with previous studies that investigated
these two dose metrics using other cell lines (11) and
a different photosensitizer (8), so there is reason to believe
that this conclusion is generalizable. Further, the results
provide additional support for the hypothesis that 1O2 is
indeed the primary cytotoxin in PDT for such photosensi-
tizers, as expected from the known photochemistry. It is still
plausible that additional secondary reactions may occur that
could cause cell damage and affect the slope of the survival
curve. However, in the absence of 3O2 (and hence
1O2),
there is negligible cell death, and thus estimates of the 1O2
dose are predictive of the PDT response. SOL monitoring
also appears to work as it should under hypoxic conditions,
even when the photosensitizer photophysics change.
By contrast, fluorescence photobleaching-based analysis
was not reliable when the pO2 was below ~5 mM. We chose
to use mTHPC as the model photosensitizer because its pho-
tobleaching was previously characterized as predominantly
1O2-mediated, whereas others, such as ALA-PpIX and Pho-
tofrin, exhibit more-complex photobleaching pathwaysBiophysical Journal 102(3) 661–671(17,24). The mTHPC fluorescence was significantly reduced
when pO2 decreased below 5 mM as a result of treatment or
gas purging. These rapid changes in fluorescence intensity
were not observed by Dysart et al. (11), most likely because
in their studies the pO2 did not reach the critical value of
4.7 mM identified above, whereas in our experiments the
pO2 often dropped below 5 mM because of the much higher
cell densities used. Hence, photobleaching-based dosimetry
may fail only for pO2 < 5 mM.
The reduction in fluorescence could be partially reversed
by reoxygenation of the sample. Perhaps the fluorescence
could be fully restored with a longer reoxygenation time;
further experiments are required to address this possibility.
This perturbation of the fluorescence signal at low [3O2]
means that 1O2 dose estimates derived from photobleaching
measurements alone are not always reliable.
To our knowledge, the biphasic rate of loss of fluores-
cence we report here has not previously been observed
in vitro. However, a similar fluorescence decay was
observed empirically in mTHPC-PDT treatments of normal
rat skin in vivo by Finlay et al. (23). This phenomenon was
fluence-rate-dependent, and occurred more readily at lower
fluence rates. Unfortunately, they did not measure [3O2] in
their experiments, so it is unclear whether the changes in
fluorescence coincided with 3O2 depletion, and whether
changes in the tissue properties could have played a role
in those results. However, the transition in the rate of loss
of fluorescence we observed is nearly identical to that pre-
sented by Finlay et al. It is important to note also that their
experiments were performed under continuous-wave light
exposure, and therefore this effect is not exclusively
a feature of the pulsed irradiation used here. As a result of
our findings, the experiments of Dysart et al. (11) were
repeated to a limited extent by one of the authors (M.S.P.)
using the same cell density, incubation times, and mTHPC
concentration as used in the studies presented here. A
similar transition in the fluorescence decay was observed.
It was most likely not observed in the original studies of
Dysart et al., who used much lower cell densities (2  106
cells/ml) where metabolic consumption is not as significant,
so that the pO2 remained above 10 mM. Note that under con-
ditions of higher oxygenation, the bleaching rates observed
here were comparable to those measured by Dysart et al.
(11). Our average photobleaching rate was 0.18 mM per
J cm2 with 524 nm irradiation, whereas Dysart et al.
showed that for an incubation concentration of 0.2 mg/ml
(z30 mM) and a fluence rate of 2 or 22 mW cm2 of
652 nm light, the bleaching rate was 0.63 mM per J cm2,
which is ~3.5-fold higher. After correction for the different
mTHPC absorption coefficients (~0.8  1015 cm2 @
524 nm and ~2 1015 cm2 @ 652 nm), the photobleaching
rates (in units of absorbed photons) are comparable.
Photobleaching rates measured by fluorescence were
also previously characterized in two different studies as
functions of [3O2] for indocarbocyanine (DiI) (25) and
Photodynamic Therapy Dosimetry 669hematoporphyrin (26) in solution. Both studies showed a
decrease in photobleaching rates with reduced [3O2] but an
apparent increase in photobleaching rate below ~5–15 mM
pO2. These results are consistent with our observations of
a rapid decrease in fluorescence when the pO2 was below
5 mM. In addition, Renn et al. (21) showed markedly higher
fluorescence in aerated samples of aromatic compounds
(e.g., DiI and Rhodamine6G) compared with 3O2-purged
samples, and noted that the fluorescence intensity increased
once the N2 flow was stopped, in similarity to our reoxyge-
nation experiments. The exact cause of the reduced fluores-
cence signal under hypoxic conditions is not known, but is
most likely linked with elongation of tT. The instantaneous
concentration of the photosensitizer triplet-state scales line-
arly with tT (17), whereas tT has an inverse dependence on
[3O2] (19). Zondervan et al. (22) suggested that the triplet
state acts as a doorway, and the longer-lived this state is,
the more pathways will open, including even longer-lived
(perhaps milliseconds) dark states that might involve radical
anion formation. Instead of being available for excitation
every 10–100 ms, molecules that enter such dark states can
only be excited every few milliseconds, thereby reducing
the total fluorescence signal. Alternatively, the reduction
could be due to the interaction of triplet-state molecules
generated from the previous pulse and a newly formed
excited-state molecule (triplet or singlet) from the succeed-
ing pulse. Currently, we have not been able to identify defin-
itively the interaction that is responsible for the reduced
fluorescence, but the photosensitizer triplet state is likely
involved.
As noted above, the onset of the 613 nm emission clearly
correlates with the drop in fluorescence, suggesting
a common link. Again, the 613 nm emission had a strong
[3O2] dependence. Because the emission is at a shorter wave-
length than the primary 652 nm fluorescence, it likely comes
from a more energetic state than the lowest-lying mTHPC
singlet state. Preliminary studies using time-resolved photon
counting suggested that the 613 nm luminescence lifetime
is a few nanoseconds, and no lifetime component compa-
rable to tT (tens of microseconds) was detected. These two
characteristics are consistent with an excimer emission
generated through the interaction of two excited-state
species (singlet-singlet, singlet-triplet, or triplet-triplet
(27)). There is also a possible explanation for this emission
occurring only below ~5 mM oxygen concentration. The
ratio of the non-3O2-mediated to
3O2-mediated triplet-state
deactivation rate constants for mTHPC is 5.0 5 1.6 mM
(19), which is similar to the value of 8.75 2.9 mM derived
for mTHPC by Mitra (28). That is, above ~5 mM, 3O2
quenching and 1O2 generation are more probable, whereas
below this level other, non-3O2-mediated deactivation
becomes more likely. If the 613 nm emission depends on
the triplet-state either linearly or quadratically (i.e., triplet-
triplet reactions), its intensity should scale with the triplet-
state concentration and lifetime, and should increase(strongly in the case of quadratic dependence) below 5 mM.
This strongly suggests that the 613 nm emission does depend
on the photosensitizer triplet-state kinetics.
Although the 613 nm emission is likely unique to
mTHPC, alternative photoluminescence signals that report
on critically low 3O2 levels can also be evaluated. For
example, it was shown for PpIX that delayed fluorescence
can be used as indicator of 3O2 concentration (29). Further-
more, some photosensitizers have relatively strong phospho-
rescence signals that might be used to identify the critical
3O2 level when fluorescence photobleaching measurements
are no longer reliable (30).
In most PDT studies, a lower fluence rate results in more
effective treatments both in vitro and in vivo, which is attrib-
uted to more efficient use of the available 3O2. At lower flu-
ence rates, reperfusion can compensate for some of the
metabolic and photochemical consumption, so that [3O2]
does not fall to zero. Conversely, at higher fluence rates,
more 1O2 is generated and the rate of photochemical deple-
tion is much greater than the 3O2 supply, so that [
3O2] rea-
ches levels (<5 mM) that limit 1O2 generation and
consequent PDT cytotoxicity. In the experiments presented
here, we used high cell densities to generate sufficient SOL
signals and to simulate the 3O2 depletion commonly
observed in vivo. As such, metabolic 3O2 consumption alone
significantly reduces the [3O2] in the sample, and this has
greater impact for longer treatments times, i.e., for lower
fluence rates. As a result, about halfway through the treat-
ment, the 3O2 becomes limiting, the
1O2 generation and
SOL counts are decreased, and the delivery of more light
causes minimal additional cytotoxicity. It is important to
stress that SOL monitoring inherently accounts for all of
these intriguing dynamics and correlates with biological
response irrespective of them.
The value of tD can be estimated from the estimate of
d via Eqs. 2 and 3, which in turn can be used to estimate
kOS. Full details on the calculations are provided in the Sup-
porting Material. Based on reasonable assumptions and esti-
mates, tD was determined to be 186 (33,þ57) ns, which is
consistent with reported values of 0.03–0.18 ms (11), 0.17–
0.32 ms (31), and 0.45 0.2 (32). Furthermore, calculations
showed kOS ¼ 2.35 0.6  107 (M1 s1), consistent with
the value of (1.2–1.7)  107 (M1 s1) measured by Dysart
et al. (11).
From the fit of Eq. 7 to the data in Fig. 5 b, the SOL signal
that corresponds to a 1/e reduction in the surviving fraction
is 4052 counts. Given that only 68% of the SOL counts arise
from inside the cells and contribute to cytotoxicity, we can
derive an estimate of 1.35 0.5 mM 1O2 dose (see Support-
ing Material for the derivation of the SOL intracellular frac-
tion and the conversion factor from counts toM). Again, this
is comparable to the range of 1.26–1.81 mM derived by
Dysart et al. (11). Further, given the cell volume and
a 50% cytosolic fraction, (4.0 5 1.7)  108 molecules of
1O2 per cell are required to reduce the survival by 1/e.Biophysical Journal 102(3) 661–671
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with mTHPC to evaluate and characterize SOL and photo-
bleaching-based PDT dosimetry. The results show that
SOL monitoring was predictive of clonogenic cell survival
under all conditions investigated. If SOL-based PDT dosim-
etry cannot be translated to the clinic because of its cost,
complexity, or very weak signal, it can still serve as an
invaluable tool (gold standard) to evaluate alternative PDT
dose metrics. Although photosensitizer photobleaching
with fluorescence measurements provides a simpler and
more practical and cost-effective approach to monitor
PDT, our studies demonstrate that it can fail under condi-
tions of low [3O2], at least for this clinical photosensitizer.
However, we identified what to our knowledge is a novel
613 nm luminescence signal, likely specific to mTHPC,
that indicates that 3O2 levels have been reached for which
fluorescence photobleaching measurement is no longer
a reliable dose metric. This could be used as a stop-or-pause
(to reoxygenate) signal to guide mTHPC-mediated PDT
treatments. Ultimately, this work improves our under-
standing of PDT dynamics and provides a platform for
developing robust dosimetry techniques to improve PDT
treatment outcomes.SUPPORTING MATERIAL
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